Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
enGene Therapeutics Inc (ENGN) had Debt to Capital Ratio of 0.10 for the most recently reported fiscal quarter, ending 2026-07-31.
| Income Statement Financials | |
-- |
|
$-32.50M |
|
-- |
|
-- |
|
$34.01M |
|
$-34.01M |
|
$1.51M |
|
$-32.50M |
|
$-32.50M |
|
$-32.50M |
|
$-32.50M |
|
$-32.50M |
|
$-32.50M |
|
$-34.01M |
|
$-34.12M |
|
69.73M |
|
69.73M |
|
$-0.47 |
|
$-0.47 |
|
| Balance Sheet Financials | |
$277.90M |
|
$2.16M |
|
$10.42M |
|
$288.32M |
|
$27.21M |
|
$25.16M |
|
$30.82M |
|
$58.03M |
|
$230.29M |
|
$230.29M |
|
$230.29M |
|
67.01M |
|
| Cash Flow Statement Financials | |
$-78.35M |
|
$-72.54M |
|
$141.76M |
|
$50.15M |
|
$41.02M |
|
$-9.13M |
|
$14.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.21 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.10 |
0.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-78.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.11% |
|
-14.11% |
|
-11.27% |
|
-12.72% |
|
$3.44 |
|
$-1.13 |
|
$-1.12 |
|